Differential proteomics analysis of synaptic proteins identifies potential cellular targets and protein mediators of synaptic neuroprotection conferred by the slow Wallerian degeneration (Wlds) gene.

Differential proteomics analysis of synaptic proteins identifies potential cellular targets and protein mediators of synaptic neuroprotection conferred by the slow Wallerian degeneration (Wlds) gene. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Differential proteomics analysis of synaptic proteins identifies potential cellular targets and protein mediators of synaptic neuroprotection conferred by the slow Wallerian degeneration (Wlds) gene. Abstract Text:

Thomas M Wishart,Janet M Paterson,Duncan M Short,Sara Meredith,Kevin A Robertson,Calum Sutherland,Michael A Cousin,Mayank B Dutia,Thomas H Gillingwater,

Non-somatic synaptic and axonal compartments of neurons are primary pathological targets in many neurodegenerative conditions, ranging from Alzheimer disease through to motor neuron disease. Axons and synapses are protected from degeneration by the slow Wallerian degeneration (Wld(s)) gene. Significantly the molecular mechanisms through which this spontaneous genetic mutation delays degeneration remain controversial, and the downstream protein targets of Wld(s) resident in non-somatic compartments remain unknown. In this study we used differential proteomics analysis to identify proteins whose expression levels were significantly altered in isolated synaptic preparations from the striatum of Wld(s) mice. Eight of the 16 proteins we identified as having modified expression levels in Wld(s) synapses are known regulators of mitochondrial stability and degeneration (including VDAC1, Aralar1, and mitofilin). Subsequent analyses demonstrated that other key mitochondrial proteins, not identified in our initial screen, are also modified in Wld(s) synapses. Of the non-mitochondrial proteins identified, several have been implicated in neurodegenerative diseases where synapses and axons are primary pathological targets (including DRP-2 and Rab GDP dissociation inhibitor beta). In addition, we show that downstream protein changes can be identified in pathways corresponding to both Ube4b (including UBE1) and Nmnat1 (including VDAC1 and Aralar1) components of the chimeric Wld(s) gene, suggesting that full-length Wld(s) protein is required to elicit maximal changes in synaptic proteins. We conclude that altered mitochondrial responses to degenerative stimuli are likely to play an important role in the neuroprotective Wld(s) phenotype and that targeting proteins identified in the current study may lead to novel therapies for the treatment of neurodegenerative diseases in humans.

Differential proteomics analysis of synaptic proteins identifies potential cellular targets and protein mediators of synaptic neuroprotection conferred by the slow Wallerian degeneration (Wlds) gene. Publishing Authors By Initials

TM Wishart,JM Paterson,DM Short,S Meredith,KA Robertson,C Sutherland,MA Cousin,MB Dutia,TH Gillingwater,

For similar pathological conditions, signs and symptoms: pathologic processes: nerve degeneration: wallerian degeneration research abstracts see: pathological conditions, signs and symptoms: pathologic processes: nerve degeneration: wallerian degeneration research

PUBMED ID PMID:

MEDLINE DATE:

Differential proteomics analysis of synaptic proteins identifies potential cellular targets and protein mediators of synaptic neuroprotection conferred by the slow Wallerian degeneration (Wlds) gene. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Molecular & cellular proteomics : MCP

VOLUME: 6

Page Numbers: 1318-30

Journal Abbreviation: Mol. Cell Proteomics

ISSN: 1535-9476

DAY: 29

MONTH: 04

YEAR: 2007

Differential proteomics analysis of synaptic proteins identifies potential cellular targets and protein mediators of synaptic neuroprotection conferred by the slow Wallerian degeneration (Wlds) gene. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101125647

Differential proteomics analysis of synaptic proteins identifies potential cellular targets and protein mediators of synaptic neuroprotection conferred by the slow Wallerian degeneration (Wlds) gene. Keywords Mesh Terms:

KEYWORDS: Wallerian Degeneration

MESH TERMS: metabolism

Chemical & Substance for Abstract: Differential proteomics analysis of synaptic proteins identifies potential cellular targets and protein mediators of synaptic neuroprotection conferred by the slow Wallerian degeneration (Wlds) gene. Information

Substance Name: Wld protein, mouse

Registry Number: 0

Grant and Affiliation Information for Differential proteomics analysis of synaptic proteins identifies potential cellular targets and protein mediators of synaptic neuroprotection conferred by the slow Wallerian degeneration (Wlds) gene.

AFFILIATION: Centres for Integrative Physiology, University of Edinburgh Medical School, Edinburgh EH8 9XD, United Kingdom.

Country: United States

AGENCY: United Kingdom Wellcome T

GRANT: GR070569

ACRONYM:

MEDLINETA: Mol Cell Proteomics

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Differential proteomics analysis of synaptic proteins identifies potential cellular targets and protein mediators of synaptic neuroprotection conferred by the slow Wallerian degeneration Wlds gene Related Publications

• Differential proteomics analysis of synaptic proteins identifies potential cellular targets and protein mediators of synaptic neuroprotection conferred by the slow Wallerian degeneration (Wlds) gene.
• Modified cell cycle status in a mouse model of altered neuronal vulnerability (slow Wallerian degeneration; Wlds).
• Selective vulnerability of motor neurons and dissociation of pre- and post-synaptic pathology at the neuromuscular junction in mouse models of spinal muscular atrophy.